Emily Forbes1,2, Thomas F Tropea2, Sneha Mantri1,3, Sharon X Xie4, James F Morley1,2. 1. Parkinson's Disease Research, Education and Clinical Center, Michael J. Crescenz Veterans Affairs Medical Center Philadelphia Pennsylvania USA. 2. Department of Neurology Perelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA. 3. Department of Neurology Duke University School of Medicine Durham North Carolina USA. 4. Department of Biostatistics, Epidemiology, and Informatics University of Pennsylvania School of Medicine Philadelphia Pennsylvania USA.
Abstract
BACKGROUND: Cognitive impairment (CI) is one of the most feared and debilitating complications of PD. No therapy has been shown to slow or prevent CI in PD. OBJECTIVE: To determine associations between modifiable comorbidities, including cardiovascular disease risk factors, mood disorders, and sleep characteristics, and rate of cognitive decline in Parkinson's disease (PD). METHODS: Data from the Parkinson's Progression Markers Initiative (PPMI) cohort was queried for baseline cardiovascular disease risk factors, mood disorders, and sleep characteristics. Linear mixed- effects models (LME) were used to examine the association between baseline factors and change in cognition, evaluated by the Montreal Cognitive Assessment (MoCA) over time. Baseline comorbidities found to affect MoCA decline were assessed for an association with focal cognitive domains using LME. RESULTS: Higher Body Mass Index (BMI) (β = -0.009, P = 0.039), State Trait Anxiety Inventory (STAI) (β = -0.005, P < 0.001), Geriatric Depression Scale (GDS) (β = -0.034, P < 0.001), Epworth Sleepiness Scale (ESS) (β = -0.017, P = 0.003), and REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) (β = -0.037, P < 0.001) were associated with faster rates of MoCA decline. Using established cut-offs for clinically significant symptoms, being overweight, or the presence of depression, excessive day time sleepiness (EDS), and possible REM sleep behavior disorder (pRBD), were all associated with faster rate of cognitive decline. CONCLUSION: Several modifiable baseline comorbidities are associated with faster rate of CI over time in patients with PD. These associations identify potential opportunities for early intervention that could influence CI in PD.
BACKGROUND: Cognitive impairment (CI) is one of the most feared and debilitating complications of PD. No therapy has been shown to slow or prevent CI in PD. OBJECTIVE: To determine associations between modifiable comorbidities, including cardiovascular disease risk factors, mood disorders, and sleep characteristics, and rate of cognitive decline in Parkinson's disease (PD). METHODS: Data from the Parkinson's Progression Markers Initiative (PPMI) cohort was queried for baseline cardiovascular disease risk factors, mood disorders, and sleep characteristics. Linear mixed- effects models (LME) were used to examine the association between baseline factors and change in cognition, evaluated by the Montreal Cognitive Assessment (MoCA) over time. Baseline comorbidities found to affect MoCA decline were assessed for an association with focal cognitive domains using LME. RESULTS: Higher Body Mass Index (BMI) (β = -0.009, P = 0.039), State Trait Anxiety Inventory (STAI) (β = -0.005, P < 0.001), Geriatric Depression Scale (GDS) (β = -0.034, P < 0.001), Epworth Sleepiness Scale (ESS) (β = -0.017, P = 0.003), and REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) (β = -0.037, P < 0.001) were associated with faster rates of MoCA decline. Using established cut-offs for clinically significant symptoms, being overweight, or the presence of depression, excessive day time sleepiness (EDS), and possible REM sleep behavior disorder (pRBD), were all associated with faster rate of cognitive decline. CONCLUSION: Several modifiable baseline comorbidities are associated with faster rate of CI over time in patients with PD. These associations identify potential opportunities for early intervention that could influence CI in PD.
Authors: Jennifer S A M Reijnders; Uwe Ehrt; Wim E J Weber; Dag Aarsland; Albert F G Leentjens Journal: Mov Disord Date: 2008-01-30 Impact factor: 10.338
Authors: Julius B M Anang; Jean-Francois Gagnon; Josie-Anne Bertrand; Silvia Rios Romenets; Veronique Latreille; Michel Panisset; Jacques Montplaisir; Ronald B Postuma Journal: Neurology Date: 2014-08-29 Impact factor: 9.910
Authors: Martijn P G Broen; Nadia E Narayen; Mark L Kuijf; Nadeeka N W Dissanayaka; Albert F G Leentjens Journal: Mov Disord Date: 2016-04-29 Impact factor: 10.338
Authors: Kara Pigott; Jacqueline Rick; Sharon X Xie; Howard Hurtig; Alice Chen-Plotkin; John E Duda; James F Morley; Lama M Chahine; Nabila Dahodwala; Rizwan S Akhtar; Andrew Siderowf; John Q Trojanowski; Daniel Weintraub Journal: Neurology Date: 2015-09-11 Impact factor: 9.910
Authors: Nadeeka N W Dissanayaka; Rachael A Lawson; Alison J Yarnall; Gordon W Duncan; David P Breen; Tien K Khoo; Roger A Barker; David J Burn Journal: Parkinsonism Relat Disord Date: 2017-01-04 Impact factor: 4.891
Authors: Samia S Islam; Sandy Neargarder; Shraddha B Kinger; Joshua T Fox-Fuller; Robert D Salazar; Alice Cronin-Golomb Journal: Gen Psychiatr Date: 2022-06-22